Table 2 Health‐related quality of life as assessed by the Short Form‐36 in patients with PAH and CTD in STRIDE‐1.
| SF‐36 domains | Placebo | Sitaxsentan | p Value* | ||
|---|---|---|---|---|---|
| Baseline (n = 9) | Change after 12 weeks | Baseline (n = 33) | Change after 12 weeks | ||
| Physical functioning | 30.3 (11.3) | −2.2 (9.3) | 29.4 (9.6) | +3.5 (7.5) | 0.042 |
| Role: physical | 34.3 (11.5) | ‐6.8 (12.0) | 31.5 (8.4) | +4.6 (10.3) | 0.01 |
| Role: emotional | 35.1 (12.3) | +4.3 (13.8) | 41.5 (12.1) | +0.4 (10.9) | 0.61 |
| Social functioning | 40.5 (11.9) | −1.2 (13.3) | 41.6 (11.6) | +2.3 (10.8) | 0.3 |
| Bodily pain | 46.2 (10.3) | +3.5 (6.6) | 44.2 (9.4) | +3.2 (8.0) | 0.67 |
| Mental health | 38.4 (11.5) | +4.4 (7.9) | 47.3 (12.7) | +2.2 (9.1) | 0.64 |
| Vitality | 41.7 (9.9) | −2.1 (7.5) | 40.8 (11.3) | +4.9 (10.5) | 0.057 |
| General health perception | 35.6 (8.7) | −1.2 (5.4) | 32.7 (8.7) | +2.8 (7.5) | 0.21 |
*Δ Sitaxsentan versus placebo at 12 weeks.
Data are mean (SD).